Disease Description
Crohn’s disease is an inflammatory bowel disease (IBD). Although Crohn’s is typically found in the last part of the small intestine and the first part of the large intestine, it can be found anywhere in the digestive tract, including the mouth and anus.
The main symptoms of Crohn’s are:
-Belly pain
-Diarrhea (sometimes with blood; some have it 10-20 times per day)
-Unexplained weight loss
-Mouth sores
-Bowel Blockages
-Anal tears
-Fistulas (opening between organs) Patients with Crohn’s may go long periods of time with no symptoms or have only a few, but some have the symptoms all the time.
Crohn's disease is an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation; it is classified as a type of inflammatory bowel disease. There has been evidence of a genetic link to Crohn's disease, putting individuals with siblings afflicted with the disease at higher risk. It is understood to have a large environmental component as evidenced by the higher number of cases in western industrialized nations. Males and females are equally affected.[1]
Prevalence
Smokers are three times more likely to develop Crohn's disease. Crohn's disease affects between 400,000 and 600,000 people in North America. Prevalence estimates for Northern Europe have ranged from 27–48 per 100,000. Crohn's disease tends to present initially in the teens and twenties, with another peak incidence in the fifties to seventies, although the disease can occur at any age.[1]
Current Treatments
There are prescription medications that can be taken to manage the symptoms, but there is no cure. At the present time, there are five basic categories of medications used in the treatment of IBD. They are:
-Aminosalicylates
-Corticosteroids
-Immunomodulators
-Antibiotics
-Biologic therapies
Medical treatment for Crohn's disease and ulcerative colitis has two main goals: achieving remission (the absence of symptoms) and, once that is accomplished, maintaining remission (prevention of flare-ups). To accomplish these goals, treatment is aimed at controlling the ongoing inflammation in the intestine—the cause of IBD symptoms.[1]
Evidence for and Proposed Mechanism for Cannabinoid Therapeutics
In a prospective clinical trial by FM Konikoff et al. it was concluded that "a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects."[2]
1. WebMD online resources
2. Konikoff FM et al. Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology. Volume 11, Issue 10, October 2013, Pages 1276–1280.e1
June 1, 2025, Pre-Launch Success! Click the below Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time Pre-Launch offer! The Time is Now.
1-Million Strong Killing Cancers!
Click the Below Image to Review our Cancer Drug Comparables
*** Warning this document contains graphic images.
CSi-VIP Awards & NASDAQ Updates
Please Click the Below Image:



The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Above ANNOUNCEMENT: December 31, 2025, Cannabis Science Inc., Shareholder Close-out.
Pease Click the above Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
Cannabis Science Financials & FINAL CBIS/CSi-VIP Share Numbers. Click the above Image link to view the latest Report.
November 5, 2025
Cannabis Science Shareholder FINAL Audit Confirmations
Click the above Image link to view the latest Report
September 23, 2025
Cannabis Science Shareholder Audit Confirmations Underway now!
Click the above Image link to view the latest Report.
July 7, 2025
Click the above Image link to view the latest cancer Killing promotional video. This is where you can join our 1-Million Strong youtube page to view more videos as we proceed forward.
June 1, 2025, Pre-Launch Success
Click the above Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time offer!
*** Warning this document contains exciting images.
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.

2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Jan 4, 2026
Hello Raymond, Francis Cormier here. Happy New Year!
Ray, November 5, 2025, was your last update to icannabinoid.com. In that update, you stated:...Jan 4, 2026
Hello Raymond, Francis Cormier here. Happy New Year!
Ray, November 5, 2025, was your last update to icannabinoid.com. In that update, you stated: I'll be sending the next CSi-EDP 'Financials/Audit UPDATE Report' in the next few days. In it, we'll officially close everything out with our in-house Financials, so we can officially start the Audit.
I am NOT a CSI-VIP Status Holder, even though I own 1.2 million original CBIS shares, so I don't receive your CSI-VIP Shareholder Legacy Reports. Therefore, I have to ask some QUESTIONS here:
(1) Have you officially closed everything out with our in-house Financials, AS STATED, so we can officially start the Audit? If not, why not?
(2) Has the AUDIT officially started? If not, why not?
Additionally, the November 5, 2025, UPDATE also time-lined the 'Audit & Pending NASDAQ Listing' activity as follows:
(1) 3-6 Months to Complete Audit Capital Raise
(2) 3-6 Months to Complete Full Audit
(3) 3-6 Months to Complete NASDAQ Filings
(4) 3-6 Months to Address Comments & Changes
QUESTIONS:
(1) Are you still in the "Raise Capital to Pay for the Audit" Step, or has that been completed already?
(2) Which of the 4 steps noted above are you currently working on?
(3) What is your conservative estimate for it to take for CBIS to be relisted on the Exchange (1-2 yrs)?
Lastly, the November 5, 2025, UPDATE does NOT speak to any current activity of the Strategic Partner "Strainsforpains." They are supposedly spearheading "Our 1-Million Strong Killing Cancer campaign." I initially thought that they were going to produce some of the CBIS Products, but just what has their contribution been? I don't see any and haven't heard of any either. I bought 23,000 shares of EBYH @ $0.26 - it is now trading for $0.16. I expected a lot more from them.
Anyway, thank you, Raymond, in advance of your response. Happy New Year.
Francis G. Cormier III
Show more
@Raymond can you share with us the SEC Filings? That would be public information right?
-
1